A placebo-controlled trial demonstrated that intrauterine instillation of the anesthetic mepivacaine effectively reduces pain during intrauterine device (IUD) placement, particularly in nulliparous patients. The findings address growing patient reports of pain during IUD insertion procedures.
Latigo has announced successful mid-stage clinical trial results for its non-opioid pain medication, positioning it as a potential competitor to Vertex Pharmaceuticals' pain drug Journavx in a field historically marked by development failures.
The U.S. Food and Drug Administration approved a nonprescription fixed-dose combination pill containing acetaminophen (650 mg) and naproxen sodium (220 mg), marketed as Tylenol with Naproxen by Kenvue. The medication provides up to 12 hours of pain relief for patients aged 12 and older.
